Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,293 people get ALXA articles and Market Currents by email alert.
Get email alerts on ALXA »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Alexza Pharmaceuticals: Forward Looking Approval Catalyst In PlayM. E. Garza • Wed, Dec 14, 2011 -
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Using Options To Benefit From The Binary Nature Of FDA DecisionsDavid Anber • Thu, Oct 18, 2012 -
-
-
-
4 Healthcare Stocks Breaking Out Mid-WeekTimeless Wealth • Thu, May 3, 2012 -
-
-
Alexza Pharmaceuticals Inc. - Special CallWed, May 8
-
Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call TranscriptMon, Nov 9, 2009
-
Alexza Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptTue, Mar 10, 2009
-
Alexza Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptTue, Nov 18, 2008
-
Alexza Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Alexza Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptMon, May 12, 2008
-
Alexza Pharmaceuticals, Inc.Q4 2007 Earnings Call TranscriptMon, Mar 17, 2008
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Mar 26, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 6, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 21, 2013)
-
PR Newswire (Jan 3, 2013)
-
at MarketWatch.com (Dec 24, 2012)
-
at MarketWatch.com (Dec 24, 2012)
-
at MarketWatch.com (Dec 21, 2012)
-
PR Newswire (Nov 6, 2012)
-
PR Newswire (Oct 18, 2012)
-
PR Newswire (Oct 17, 2012)
ALXA vs. ETF Alternatives
Company Description
We are a pharmaceutical company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS, conditions. All of our product candidates are based on our proprietary technology, the Staccato system. The... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 15, 6:32 AM Alexza Pharmaceuticals (ALXA): Q1 EPS of -$1.31 misses by $0.86. Revenue of $729K beats by $271M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Wednesday, May 8, 12:53 PM
Midday top 10 gainers: TRMD +68%. SYNM +35%. AFFY +35%. ALXA +25%. CSPI +21%. PSE +21%. NBG +20%. WBMD +18%. SCOK +17%. EA +16%.
Midday top 10 losers: FIO -25%. OCLR -23%. LIOX -18%. VCLK -17%. AXLL -16%. OCLS -15%. BTH -15%. SALM -13%. ACFC -12%. SNTA -12%. Comment! [On the Move] -
Wednesday, May 8, 9:17 AM
Premarket gainers: ALXA +51%. PSE +19%. LEDR +16%. NBG +11%. WFM +8%. EA +6%. PRTS +6%. SFUN +6%. CTSH +5%.
Losers: FIO -22%. VCLK -19%. OCLR -19%. AXLL -9%. CIE -7%. CHRW -7%. SODA -6%. DDD -6%. SYMC -5%. Z -5%. VVUS -5%. Comment! [On the Move] - Wednesday, May 8, 9:11 AM Alexza Pharmaceuticals (ALXA) comes off trading halt, now up 52% premarket following the license deal with Teva (TEVA +0.3% premarket). The conference call discussing the matter is underway. 3 Comments [Breaking News, Healthcare, On the Move]
- Wednesday, May 8, 9:00 AM Alexza Pharmaceuticals (ALXA) announces an exclusive U.S. license deal for Adasuve with Teva Pharmaceutical (TEVA). Nice deal for Alexza - it will receive an upfront payment of $40M with eligibility for another $195M based on milestones. Conference call to discuss is about to begin. Shares remains halted. (PR) Comment! [Healthcare, Breaking News]
- Wednesday, May 8, 8:31 AM Alexza Pharmaceuticals (ALXA) is halted from trading with news pending. Comment! [Breaking News, Healthcare]
- Wednesday, April 3, 11:03 AM Alexza Pharmaceuticals (ALXA +4%) gives back a little but remains firmly in the green following a +7% run-up during the pre-open session on an earlier upgrade from Piper Jaffray to Overweight. Piper notes that it's channel checks with ER physicians, psychiatrists, and opinion leaders was even more encouraging than it expected on both the near and longer-term market potential for Adasuve versus previous projections. Additionally, it's clinical attributes bode well for a value-added partnership being signed soon to enable effective launch in Q3. 1 Comment [Healthcare, On the Move]
- Wednesday, April 3, 9:25 AM Alexza Pharmaceuticals (ALXA) is trading higher before the bell after Piper Jaffray upgrades the stock to Overweight from Neutral. Shares +7.3% premarket. 1 Comment [Healthcare]
-
Wednesday, April 3, 9:10 AM
Premarket gainers: CALL +14%. CONN +10%. ZNGA +10%. ASTX +10%. UNXL +9%. AWRE +9%. OMPI +9%. NVAX +9%. ALXA +8%. MHR +7%. NFX +6%.
Losers: MSPD -19%. GPN -7%. 3 Comments [On the Move] - Tuesday, March 26, 5:44 PM More on Alexza Pharmaceuticals (ALXA): Q4 EPS misses expectations, with revenues coming at $729K, well below estimates of $3.48M. In the same period last year, the company reported a loss per share of $1.34 on revenues of $1.88M. R&D expenses were lower for the quarter, largely as a result of the suspension of development of AZ-007 and Staccato nicotine product candidates starting in late 2011, as well as efforts to conserve cash. Comment! [Healthcare, Earnings]
- Tuesday, March 26, 5:15 PM Alexza Pharmaceuticals (ALXA): Q4 EPS of -$0.65. Revenue of $729K. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
- Thursday, February 21, 9:41 AM The EU approves Alexza Pharmaceuticals' (ALXA +2.2%) Adasuve, a treatment for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The authorization adds to FDA backing. Alexza plans to launch Adasuve in the U.S. and EU in Q3. (PR) 1 Comment [Healthcare]
-
Thursday, February 21, 9:10 AM
Premarket gainers: PRKR +38%. RPRX +31%. NVGN +28%. BRY +22%. PEGA +17%. LOCK +7%. LNCO +5%. ALXA +5%.
Losers: GENT -37%. PAY -34%. GFI -17%. ALU -7%. WLT -6%. TSLA -5%. Comment! [On the Move] -
Monday, December 24, 2012, 2:57 PM
After-hours top gainers, as of 2:30 p.m.: TVIX +3.6%. UVXY +3.1%. VXX +1.9%. SE +1.6%. ALXA +1.6%.
After-hours top losers: UGAZ -2.1%. XIV -1.7%. SVXY -1.7%. AIG -1.6%. ABB -1.3%. Comment! [On the Move] -
Monday, December 24, 2012, 11:15 AM
Midday top 10 gainers: ATV +34%. CT +18%. ALIM +12%. CLSN +12%. EJ +11%. EDAP +11%. GSS +11%. RGLS +10%. AVEO +10%. EGLE +10%.
Top 10 Losers: MHH -30%. TLAB -27%. ALXA -14%. XRTX -12%. AMPL -11%. CIG -10%. SVA -9%. ISS -9%. MITL -8%. RPTP -8%. 1 Comment [On the Move] - Monday, December 24, 2012, 9:10 AM Premarket Losers: TLAB -26%. ALXA -11%. Comment! [On the Move]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.